SLC5A1 and type 2 diabetes mellitus: Yakovleva et al. (2019) used qantitative drug–disease systems model of dapagliflozin canagliflozin and empagliflozin to demonstrated that SGLT1-mediated transporter capacity was greater in T2DM.